BSIM has attended the 2nd European ATTR amyloidosis Meeting for Doctors and Patients

BSIM Therapeutics is awarded a United States Patent (Patent #10,377,729) for one of its promising technologies in the stabilization of transthyretin (TTR)

Results published in Amyloid, The Journal, show that one of the technologies developed by BSIM Therapeutics stabilizes transthyretin in the cerebrospinal fluid and in the vitreous humor.

BSIM Therapeutics was one of the 25 companies selected for participation in the Accelerator Program of the European project Invest Horizon The kick-off event took place from June 3rd to 7th, 2019, in Paris.